Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
about
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataClinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementationDrug Metabolism - From In Vitro to In Vivo, From Simple to Complex: Reflections of the BCPT Nordic Prize 2014 AwardeeGene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomesEffects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteersAssessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice.Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information.Bupropion for the treatment of seasonal affective disorder.Bupropion: pharmacology and therapeutic applications.Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of hemeCardiovascular pharmacogenomicsEffect of renal impairment on the pharmacokinetics of bupropion and its metabolitesRisk assessment of mechanism-based inactivation in drug-drug interactions.Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men.Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping indexRapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavirNaltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults.Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceUse of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseasesPolymorphic CYP2B6: molecular mechanisms and emerging clinical significance.Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MSRole of cytochrome P4502B6 in methadone metabolism and clearance.New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.PhRMA white paper on ADME pharmacogenomics.Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel.Pharmacokinetic basis of the antiplatelet action of prasugrel.Clinically significant drug interactions with newer antidepressants.Clinically-relevant anticancer-antidepressant drug interactions.Metabolic differences of current thienopyridine antiplatelet agents.Pharmacogenomics of anti-platelet and anti-coagulation therapy.Clinical pharmacokinetics and pharmacodynamics of clopidogrel.Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.A strategy for early-risk predictions of clinical drug-drug interactions involving the GastroPlusTM DDI module for time-dependent CYP inhibitors.Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4'-OH-bupropion in vitro.Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjectsDecreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.
P2860
Q27009128-FA3FE1BC-1012-4997-9D9C-DA4FE9830904Q27011524-EAE9B350-D018-4BB6-B013-759A43C70CBEQ28083049-12D85907-43EE-41D5-8F6B-2AC7D070C7A5Q28247305-397F4301-DD63-4C94-9C9F-C9AA74B2B7A4Q28750369-377E4329-11F5-498E-B7AA-2C94595489D1Q30688345-1E74C6DB-6278-45B7-80B8-75D2E1065734Q34217306-57CBE32E-B49E-49C2-992C-40F2E2E6EC92Q34250313-EB22929C-10B2-4A9E-8F35-8320055C593FQ34346558-687BA046-4E73-4ABF-898D-7C8E4AF96070Q34569990-DF713662-DEDF-429F-B496-011E41AF61C7Q35415762-F0C9812A-47CD-4B48-8F4B-BE61C054BEF7Q35447163-9EE09D0B-F927-428A-AC99-C09E785BB183Q36024598-4B841349-DD6F-4CF2-B1C0-2A31EB939F89Q36174265-B7B9F624-8CE0-481E-A8B2-A186D3B3698BQ36468142-5833B3CE-B77A-4C09-A348-6D43B979B198Q36562516-69D83DBA-9C24-40A4-B408-00851D97D344Q36593838-6DE405B9-21A3-4314-AAE9-01AB24F84B64Q36630609-9E9FFBCB-0A90-4A10-8585-885C8C2FC933Q36652680-03B34899-0FC3-4BE1-B707-8C8C13D9EB21Q36657589-5F1BF7B6-1D9B-4AE8-87F3-D4876930790DQ36733922-7DF08B7A-2695-4F74-B489-FD83D812B91FQ36885659-31A38F87-4DC6-46B1-BB04-9A2D26C70529Q36900154-9DB051A1-5F80-43F3-9E69-791D3B14EB6BQ37094439-A7706B81-6682-4802-919E-E4E09A942506Q37124261-9DF1F004-DC22-4C20-B6F8-2288A97FF6DBQ37182212-58A70458-8DD2-4FF3-8BFB-5C282B3A2E04Q37641606-F529C148-47CC-48CD-AF29-B5C10EE4AA08Q37835616-92CE5358-4081-49FC-8557-F2BCD6E7EDA6Q37927151-6CD071FA-2C45-43A6-AFAA-A83AA5F9BEDAQ37968621-555A121E-B57F-4EBA-B57E-9DA6AE8E7846Q37970709-5C34806C-5AB4-484C-96C4-A23EB793ABAFQ38071707-22D1E72B-9E0C-4A8F-9698-F4CE5C1DB954Q38116753-FEEC6A1A-F1B8-4B37-A97E-A7EC4425365AQ38307535-32F2913A-6B83-42BA-BFB0-069D46FD9060Q38815352-0B730438-2A93-4391-AA3F-C3339A07FB80Q38819541-DF72555E-5BDF-4B35-8542-152E62432D1DQ39519725-63B1B9E3-DC77-444B-BCCF-57B55FAD7E1FQ41153557-2AF6F9B1-5406-42F9-8B75-5752A274AB96Q42008173-177F5E56-94CA-4251-A68C-3E35C31824ABQ42217729-2EDD5C55-6B16-420B-A05F-617E23A10BDE
P2860
Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Effect of clopidogrel and ticl ...... ed by bupropion hydroxylation.
@en
Effect of clopidogrel and ticl ...... ed by bupropion hydroxylation.
@nl
type
label
Effect of clopidogrel and ticl ...... ed by bupropion hydroxylation.
@en
Effect of clopidogrel and ticl ...... ed by bupropion hydroxylation.
@nl
prefLabel
Effect of clopidogrel and ticl ...... ed by bupropion hydroxylation.
@en
Effect of clopidogrel and ticl ...... ed by bupropion hydroxylation.
@nl
P2093
P1476
Effect of clopidogrel and ticl ...... ed by bupropion hydroxylation.
@en
P2093
Ari Tolonen
Jorma Jalonen
Jouko Uusitalo
Kari Laine
Olavi Pelkonen
P304
P356
10.1016/J.CLPT.2005.02.010
P407
P577
2005-06-01T00:00:00Z